Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients
Rebecca Evans, Emmanuel Mignot(Stanford University), Ceri H. Davies, Shinichiro Tanaka(National Hospital Organization), Hélène M. Faessel(Takeda (Japan)), Hiroshi Yukitake(Takeda (Japan)), Haruhide Kimura(Takeda (Japan)), Motohisa Suzuki(Takeda (Japan)), Yves Dauvilliers(Inserm), Robert Alexander(Pfizer (United States)), Deborah Hartman(Avaxia Biologics (United States)), Emiliangelo Ratti(Takeda (United States)), Kohei Shimizu(Takeda (Japan)), Takashi Ishikawa(Akita University)
Cited by 92
Related Papers
National Sleep Foundation's sleep quality recommendations: first report
|Sleep Health|2016|1.3k
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study
|Brain|2019|1.1k
Narcolepsy with cataplexy
|The Lancet|2007|716
Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment
|Nature Reviews Neurology|2019|634
REM sleep behaviour disorder
|Nature Reviews Disease Primers|2018|498